(Press-News.org) A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.
The trial findings will be published in the Journal of Clinical Oncology (JCO) and presented at the European Hematology Association Congress in Milan, Italy, both on June 12. Joshua F. Zeidner, MD, associate professor of medicine and chief of leukemia research at UNC Lineberger and the UNC School of Medicine, is the paper’s corresponding author and will deliver the presentation.
AML is a very heterogeneous disease with more than a dozen different subtypes. This warrants a personalized treatment approach given the distinct biology of each genetic subtype.
The National Cancer Institute estimates that more than 20,000 Americans will be diagnosed with AML this year, and approximately 11,000 will die from the disease. The overall five-year survival rate is about 33%, but this drops to roughly 17% for individuals over the age of 60 — the age group represented in this trial.
In this study, the investigators were looking at AML with two specific gene alterations: nucleophosphmin-1 (NPM1m) or lysine methyltransferase 2A (KMT2Ar) rearrangements. NPM1m is the common mutation in AML seen in about 30% of AML patients whereas KMT2Ar is relatively rare, seen in about 5% of AML patients. Notably, both alterations share a gene expression profile that contributes to the development and progression of AML. A new class of targeted agents known as menin inhibitors has been shown to be clinically active in patients with these alterations. Revumenib is an oral menin inhibitor that is approved for patients with relapsed AML with a KMT2Ar alteration.
The study was part of the Leukemia and Lymphoma Society’s Beat AML Master Clinical Trial protocol that uses advanced genomic technology to identify gene alterations associated with each patient’s leukemia. With this technology, the patient’s unique genomic profile can be ascertained within 3 to 5 days of a blood draw and genomic testing. This information is then used to create an individualized treatment approach for each patient with AML.
This phase 1 clinical trial is the first to investigate whether adding a menin inhibitor to the standard therapy is safe and effective for newly diagnosed older adults with AML The study enrolled 43 patients at 12 centers nationwide. The patients were given a combination of the current standard of care, azacitidine and venetoclax, two established chemotherapy drugs, with revumenib.
The overall response rate, defined as no evidence of leukemia, was 88.4%. The complete remission rate, meaning no evidence of leukemia along with normal blood counts, was 67.4%. These response rates are higher than expected compared to the current standard of care.
All patients responded to the treatment after one to two 28-day cycles; 84% of responders achieved remission within the first cycle. After one year on the trial, 62.9% of patients were still alive.
“The promising findings from our phase 1 safety trial have directly led to the design and implementation of a randomized phase 3 study to determine whether the addition of revumenib to standard azacitidine and venetoclax improves overall survival in people with NPM1m or KMT2Ar AML,” Zeidner said. “This regimen has the potential to be practice-changing for patients whose AML harbors the specific gene alterations we focused on.”
Zeidner will be the lead U.S. investigator for the phase 3 trial and UNC Lineberger will serve as the lead site.
“As there are only 12 centers currently part of the Beat AML consortium, we are adding an additional 10 to 12 U.S. centers in order to successfully launch this study. The phase 3 trial will be led by the HOVON group, a European Cooperative Oncology Group, to make the phase 3 trial as robust as possible and hopefully provide definitive evidence of the efficacy of this drug combination,” Zeidner said.
END
Novel drug combination is safe and benefits people with acute myeloid leukemia who have a specific genetic profile
2025-06-12
ELSE PRESS RELEASES FROM THIS DATE:
Sleep apnea more common than previously known in female athletes
2025-06-12
According to a new study, presented at the American College of Cardiology (ACC) Care of the Athletic Heart 2025 conference, sleep apnea may be more prevalent in younger female athletes than previously believed, especially among female athletes with higher levels of training. While obstructive sleep apnea has been observed in younger male athletes, the prevalence in female athletes and the association with cardiovascular risk is largely unknown.
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder, impacting about 18 million Americans, and is prevalent in both men and women. It occurs when the throat muscles relax and ...
Study: Eating more fruits and veggies could help you sleep better
2025-06-12
From counting sheep to white noise and weighted blankets, people have tried innumerable ways to get a good night’s sleep. Sleep disruptions can have far-reaching negative consequences, impacting cardiovascular and metabolic health, memory, learning, productivity, mood regulation, interpersonal relationships and more.
It turns out that an important tool for improving sleep quality may have been hiding in plain sight…in the produce aisle. A new study led by researchers at the University of Chicago Medicine and Columbia University found that eating more fruits and vegetables during the day was associated with sleeping more soundly later that same ...
Intravenous fluid study illustrates powerful, efficient approach for comparative clinical trials
2025-06-12
A clinical trial led by researchers at The Ottawa Hospital and the University of Ottawa and published in the New England Journal of Medicine illustrates a powerful and efficient approach for comparing different standard treatments. The FLUID trial compared two intravenous fluids that have been commonly used for decades in hospitalized patients: normal saline and Ringer's lactate. Many millions of litres of these fluids are used every year in Canada alone, and there is no strong evidence favouring one over the other across the hospital.
Unlike a traditional trial, which would randomly assign each patient ...
Lithium supply will fall short of growing electric vehicle demand through 2029
2025-06-12
In a study publishing June 12 in the Cell Press journal Cell Reports Sustainability, researchers conducted the most comprehensive analysis to date on lithium supply and demand in China, Europe, and the USA. Despite that domestic lithium production in some of these regions could grow as much as 10 times by 2030, it would still fall short of the soaring demand for electric vehicles (EVs) without expanding imports or technological innovation.
“Lithium today is as important as gasoline in the industrial revolution,” says author Qifan Xia of East China Normal University in Shanghai. “While lithium reserves are substantial around the world, they are distributed ...
Humans have unique breathing “fingerprints” that may signal health status
2025-06-12
Your breath is one of a kind. A study published June 12 in the Cell Press journal Current Biology demonstrated that scientists can identify individuals based solely on their breathing patterns with 96.8% accuracy. These nasal respiratory “fingerprints” also offer insights into physical and mental health.
The research stemmed from the lab’s interest in olfaction, or the sense of smell. In mammals, the brain processes odor information during inhalation. This link between the brain and breathing led researchers to wonder: since every brain is unique, wouldn’t ...
Turning back time on muscle stem cells to prevent frailty from aging
2025-06-12
The population across developed countries is getting older and the associated frailty and debilitation are becoming major health problems. This gradual muscle loss is accelerated by the poor capacity to repair damage and injury, especially after falls or surgeries.
Low muscle mass in the elderly — known as sarcopenia — leads to increased frailty and movement problems. Patients with sarcopenia are more likely to be hospitalized and develop other comorbidities, largely due to falls and fractures that tend to create health declines that quickly spiral out of control.
“We knew that a major contributor is the muscle stem cells that are needed to repair ...
Giving NK cells the upper hand in the battle against cancer
2025-06-12
All of us produce a growth factor – called IL-15 – which effectively protects us from cancers. It’s role is to boost the production of immune cells that can rapidly detect and kill cancer cells when they first appear. One of these cell-types is appropriately called Natural Killer Cells.
The problem is that cancer cells evolve numerous strategies to suppress immune cells like NK cells, even when these cancer cell are producing the immune boosting factor IL-15, and too often the cancer cells win. ...
Targeted management of invasive species could reduce EU species extinction risk by 16%
2025-06-12
Gland, Switzerland (IUCN) –Experts from the International Union for Conservation of Nature (IUCN) have analysed how targeted management of invasive alien species (IAS) can reduce extinction risks for threatened species across the European Union (EU), in line with the EU Biodiversity Strategy for 2030.
Published in the open-access journal NeoBiota, and funded by the European Commission, a new study identifies where and how targeted action against IAS (species that have been introduced to areas outside their ...
Decline in US drug overdose deaths by region, substance, and demographics
2025-06-12
About The Study: In this cross-sectional study, U.S. drug overdose death rates entered a new wave of sustained deceleration in 2023 after 2 decades of increase. This shift may reflect changes in drug markets, treatment access, harm reduction efforts, and population-level risk. Although the decline is encouraging, persistent disparities highlight the need for targeted interventions and improved understanding of the underlying drivers.
Corresponding Author: To contact the corresponding author, Lori Ann Post, PhD, email lori.post@northwestern.edu.
To access the embargoed study: Visit our For The ...
Long-term effectiveness associated with fecal immunochemical testing for early-age screening
2025-06-12
About The Study: This study found that initiating fecal immunochemical test screening at age 40 to 49 was associated with further reduction in colorectal cancer (CRC) mortality and incidence compared with starting screening at age 50. These results provide strong empirical support for lowering the CRC screening age, with substantial public health implications.
Corresponding Author: To contact the corresponding author, Tony Hsiu-Hsi Chen, PhD, email chenlin@ntu.edu.tw.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2025.1433)
Editor’s ...